These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 4821036)

  • 1. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress.
    Barry M; Flynn DM; Letsky EA; Risdon RA
    Br Med J; 1974 Apr; 2(5909):16-20. PubMed ID: 4821036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassaemia.
    Risdon RA; Barry M; Flynn DM
    J Pathol; 1975 Jun; 116(2):83-95. PubMed ID: 1151528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum ferritin in children with thalassaemia regularly transfused.
    Letsky EA; Miller F; Worwood M; Flynn DM
    J Clin Pathol; 1974 Aug; 27(8):652-5. PubMed ID: 4421996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study.
    Maurer HS; Lloyd-Still JD; Ingrisano C; Gonzalez-Crussi F; Honig GR
    Am J Dis Child; 1988 Mar; 142(3):287-92. PubMed ID: 3344715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depletion of excessive liver iron stores with desferrioxamine.
    Cohen A; Martin M; Schwartz E
    Br J Haematol; 1984 Oct; 58(2):369-73. PubMed ID: 6477838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
    N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relation between liver iron concentration and liver damage in transfusional iron overload in thalassaemia and the effect of chelation therapy.
    Risdon RA; Flynn DM; Barry M
    Gut; 1973 May; 14(5):421. PubMed ID: 4716515
    [No Abstract]   [Full Text] [Related]  

  • 8. Proceedings: 5-year controlled trial of chelating agents in treatment of thalassaemia major.
    Flynn DM
    Arch Dis Child; 1973 Oct; 48(10):829. PubMed ID: 4584225
    [No Abstract]   [Full Text] [Related]  

  • 9. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R; Piga A; Harmatz P; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine.
    Aldouri MA; Wonke B; Hoffbrand AV; Flynn DM; Laulicht M; Fenton LA; Scheuer PJ; Kibbler CC; Allwood CA; Brown D
    J Clin Pathol; 1987 Nov; 40(11):1353-9. PubMed ID: 3121679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
    Wu SF; Peng CT; Wu KH; Tsai CH
    Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of treatment with long-term chelating agents on iron overload in thalassaemia.
    Letsky EA; Flynn DM; Barry M
    Br J Haematol; 1973 Aug; 25(2):285. PubMed ID: 4726921
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial: Thalassemia major: a problem of iron overload.
    Stockman JA; Oski FA
    Ann Intern Med; 1974 Aug; 81(2):262-3. PubMed ID: 4846109
    [No Abstract]   [Full Text] [Related]  

  • 14. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
    Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron excretion in thalassemia after the administration of chelating agents.
    Markum AH; Iskandar W; Keng KL; Odang O
    Paediatr Indones; 1969; 9(3):89-98. PubMed ID: 4981722
    [No Abstract]   [Full Text] [Related]  

  • 17. Chelation therapy for the treatment of thalassemia.
    Graziano JH; Cerami A
    Semin Hematol; 1977 Jan; 14(1):127-34. PubMed ID: 318766
    [No Abstract]   [Full Text] [Related]  

  • 18. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Roberts DJ; Rees D; Howard J; Hyde C; Alderson P; Brunskill S
    Cochrane Database Syst Rev; 2005 Oct; (4):CD004450. PubMed ID: 16235363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of desferrioxamine chelation versus no therapy in patients with non transfusion-dependent thalassaemia: a multicenter prospective comparison from the MIOT network.
    Ricchi P; Meloni A; Pistoia L; Spasiano A; Spiga A; Allò M; Gamberini MR; Lisi R; Campisi S; Peluso A; Missere M; Renne S; Mangione M; Positano V; Pepe A
    Ann Hematol; 2018 Oct; 97(10):1925-1932. PubMed ID: 29926157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
    Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.